Pharmacologic Treatment of Vitiligo in Children and Adolescents: A Systematic Review

Menezes, Andreia Freire de; Carvalho, Fernanda Oliveira de; Barreto, Rosana S.S.; Silva, Bruno de Santana; Saravanan, S.; Gurgel, Ricardo Queiróz; Araújo, Adriano Antunes de Souza

doi:10.1111/pde.13024

Cited by 13 publications

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…22 Systematic reviews and meta-analyses support a combination approach consisting of TCIs and phototherapy in the form of narrow-band ultraviolet B radiation 23,24 or 308-nm excimer laser therapy. 25,26 British guidelines suggest TCIs may be considered for adults and children with vitiligo as an alternative to TCS given their better short-term safety profile. 27 ii) Types of Dermatitis Other Than Atopic Dermatitis.…”

Section: Off-label Use Of Tcis That Is Well Supported By the Literaturementioning

confidence: 99%

Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders

2019

View full text Add to dashboard Cite

Off-label prescribing is a common practice in dermatology, particularly when uncommon dermatologic diseases have limited or no approved treatment options. Topical calcineurin inhibitors are approved for the treatment of eczema, and their anti-inflammatory, immunomodulatory, and steroid-sparing effects make them an attractive therapeutic option for a wide variety of other dermatologic diseases. This review summarizes and qualifies the available evidence supporting the clinical effectiveness of tacrolimus ointment and pimecrolimus cream in non-eczema indications. There is high-quality evidence supporting the effectiveness of topical calcineurin inhibitors in multiple dermatological disorders including vitiligo; psoriasis of the face, folds, and genitals; seborrheic dermatitis; chronic hand dermatitis; contact dermatitis; oral lichen planus; lichen sclerosus; morphea; and cutaneous lupus erythematosus. Lower-quality evidence suggests they may be considered as an option in many other cutaneous disorders.

show abstract

Section: Off-label Use Of Tcis That Is Well Supported By the Literaturementioning

confidence: 99%

Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders

2019

View full text Add to dashboard Cite

show abstract

“…This dermatologic disorder is caused by abnormal melanocytes. The exact cause of vitiligo is still unclear, but studies have suggested a wide range of causes from autoimmunity to autocytotoxicity to viral and neural causes [43] , [50] . One vitiligo treatment is to expose the skin to UVB light to induce repigmentation [51] .…”

Section: Resultsmentioning

confidence: 99%

The skin protective effects of compound K, a metabolite of ginsenoside Rb1 from Panax ginseng

Kim

Yoo

et al. 2018

Journal of Ginseng Research

View full text Add to dashboard Cite

BackgroundCompound K (CK) is a ginsenoside, a metabolite of Panax ginseng. There is interest both in increasing skin health and antiaging using natural skin care products. In this study, we explored the possibility of using CK as a cosmetic ingredient.MethodsTo assess the antiaging effect of CK, RT-PCR was performed, and expression levels of matrix metalloproteinase-1, cyclooxygenase-2, and type I collagen were measured under UVB irradiation conditions. The skin hydrating effect of CK was tested by RT-PCR, and its regulation was explored through immunoblotting. Melanin content, melanin secretion, and tyrosinase activity assays were performed.ResultsCK treatment reduced the production of matrix metalloproteinase-1 and cyclooxygenase-2 in UVB irradiated NIH3T3 cells and recovered type I collagen expression level. Expression of skin hydrating factors—filaggrin, transglutaminase, and hyaluronic acid synthases-1 and -2—were augmented by CK and were modulated through the inhibitor of κBα, c-Jun N-terminal kinase, or extracellular signal-regulated kinases pathway. In the melanogenic response, CK did not regulate tyrosinase activity and melanin secretion, but increased melanin content in B16F10 cells was observed.ConclusionOur data showed that CK has antiaging and hydrating effects. We suggest that CK could be used in cosmetic products to protect the skin from UVB rays and increase skin moisture level.

show abstract

“…In a systematic review, the most commonly used drugs were tacrolimus alone (or combined with clobetasol), pimecrolimus, corticosteroids, and calcipotriol. 11 All these methods may have consequences in the short, medium or long run on the health of the patient. In addition to the fact that no therapy is planned, we have envisaged psychotherapy when the child will become aware of his unsightly lesions.…”

Section: Discussionmentioning

confidence: 99%

Congenital Vitiligo: A Case Observed in the Cohort of HIV-Exposed Infants in Bobo-Dioulasso, Burkina Faso

et al. 2017

View full text Add to dashboard Cite

Vitiligo is a dermatological disease; its exact prevalence is unknown among the paediatric population. We are reporting a case of vitiligo at birth for the first time in Burkina Faso, in the Teaching Hospital Souro Sanou of Bobo-Dioulasso, Paediatric Department. He is a male child, born from HIV-1 positive parents; we received him when he was 2 months to be followed in connection with the prevention of motherto-child transmission. He showed achromic lesions on the skin and on skin appendages at birth. In addition to congenital vitiligo we mentioned, several diagnostic hypotheses were discussed. No treatment was decided to face these skin lesions given the very young age of the patient. Psychological support is planned in the long run.

show abstract

Pharmacologic Treatment of Vitiligo in Children and Adolescents: A Systematic Review

Cited by 13 publications

References 39 publications

Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders

Off-Label Use of Topical Calcineurin Inhibitors in Dermatologic Disorders

The skin protective effects of compound K, a metabolite of ginsenoside Rb1 from Panax ginseng

Congenital Vitiligo: A Case Observed in the Cohort of HIV-Exposed Infants in Bobo-Dioulasso, Burkina Faso

Contact Info

Product

Resources

About